Sight Sciences, Inc. (SGHT)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1531177 · fiscal year ends in Dec
Closing price $9.56 on 29 Oct 2026; 52-week range $3.45 to $9.56.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $83.4M
- Revenue growth
- 9.3%
- Net income, last twelve months
- -$29.8M
- Earnings per share
- -$0.56
- Gross margin
- 88.0%
- Operating margin
- -33.4%
- Net margin
- -35.7%
- Return on equity
- -56.3%
- Market value
- $523.4M
- Cash
- $79.8M
- Debt
- $40.8M
- Debt to equity
- 0.77
- Shares outstanding
- 54.7M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $77.4M | -$37.1M | -$38.4M | -$0.74 | -$29.9M | 10-K filed 4 Mar 2026 |
| FY2024 | 31 Dec 2024 | $79.9M | -$50.5M | -$51.5M | -$1.03 | -$22.7M | 10-K filed 7 Mar 2025 |
| FY2023 | 31 Dec 2023 | $81.1M | -$57.3M | -$55.5M | -$1.14 | -$48.0M | 10-K filed 13 Mar 2024 |
| FY2022 | 31 Dec 2022 | $71.3M | -$84.0M | -$86.2M | -$1.80 | -$76.9M | 10-K filed 16 Mar 2023 |
| FY2021 | 31 Dec 2021 | $49.0M | -$51.5M | -$63.0M | -$2.36 | -$53.4M | 10-K filed 24 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $23.4M | -$4.4M | -$0.08 |
| Q1 FY2026 | 31 Mar 2026 | $19.7M | -$13.0M | -$0.24 |
| Q4 FY2025 | 31 Dec 2025 | $20.4M | -$4.2M | -$0.08 |
| Q3 FY2025 | 30 Sep 2025 | $19.9M | -$8.2M | -$0.16 |
| Q2 FY2025 | 30 Jun 2025 | $19.6M | -$11.9M | -$0.23 |
| Q1 FY2025 | 31 Mar 2025 | $17.5M | -$14.2M | -$0.28 |
| Q4 FY2024 | 31 Dec 2024 | $19.1M | -$11.8M | -$0.23 |
| Q3 FY2024 | 30 Sep 2024 | $20.2M | -$11.1M | -$0.22 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Interventional Glaucoma | $75.7M | 97.9% |
| Interventional Dry Eye | $1.6M | 2.1% |
Company events
The newest 8-K filings of 66 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 10 Aug 2026 | 8-K | Leadership change | 5.02 |
| 5 Aug 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 5 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 6 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 23 Apr 2026 | 8-K | Investor update | 7.01, 9.01 |
| 30 Mar 2026 | 8-K | Investor update | 7.01, 9.01 |
| 4 Mar 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 3 Feb 2026 | 8-K | Material agreement | 1.01 |
| 13 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 6 Nov 2025 | 8-K | Results, Leadership change, Investor update | 2.02, 5.02, 7.01, 9.01 |
| 17 Oct 2025 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 30 Sep 2025 | 8-K | Material agreement | 1.01, 9.01 |
Every filing
The newest filings with the SEC of 132 held.
| Filed | Form | Period |
|---|---|---|
| 10 Aug 2026 | 8-K | 6 Aug 2026 |
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 5 Aug 2026 | 8-K | 5 Aug 2026 |
| 5 Jun 2026 | 8-K | 4 Jun 2026 |
| 29 May 2026 | SD | – |
| 6 May 2026 | 10-Q | 31 Mar 2026 |
| 6 May 2026 | 8-K | 6 May 2026 |
| 23 Apr 2026 | 8-K | 22 Apr 2026 |
| 22 Apr 2026 | DEFA14A | – |
| 22 Apr 2026 | DEF 14A | 4 Jun 2026 |
| 30 Mar 2026 | 8-K | 27 Mar 2026 |
| 4 Mar 2026 | 10-K | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 2 Oct 2026 | Taylor Brenton, EVP, Operations & R&D | Sale under a trading plan | 2,988 | $8.85 | $26.5K | 261,990 | 5 Oct 2026 |
| 2 Oct 2026 | Bauerlein Alison, Chief Operating Officer | Sale under a trading plan | 25,260 | $8.85 | $223.6K | 639,449 | 5 Oct 2026 |
| 2 Oct 2026 | Rodberg James, Chief Financial Officer | Sale under a trading plan | 7,208 | $8.85 | $63.8K | 216,829 | 5 Oct 2026 |
| 1 Oct 2026 | Badawi David, Chief Technology Officer | Sale under a trading plan | 7,797 | $9.05 | $70.6K | 1,975,075 | 5 Oct 2026 |
| 1 Oct 2026 | Badawi Paul, President and CEO | Sale under a trading plan | 29,653 | $9.05 | $268.3K | 6,092,819 | 5 Oct 2026 |
| 6 Jul 2026 | Hayden Jeremy B., Chief Legal Officer | Sale under a trading plan | 12,733 | $5.51 | $70.1K | 357,037 | 6 Jul 2026 |
| 6 Jul 2026 | Badawi David, Chief Technology Officer | Sale under a trading plan | 7,418 | $5.51 | $40.9K | 1,982,872 | 6 Jul 2026 |
| 2 Jul 2026 | Rodberg James, Chief Financial Officer | Sale under a trading plan | 6,902 | $5.36 | $37.0K | 224,037 | 6 Jul 2026 |
| 2 Jul 2026 | Bauerlein Alison, Chief Operating Officer | Sale under a trading plan | 24,184 | $5.36 | $129.6K | 664,709 | 6 Jul 2026 |
| 1 Jul 2026 | Taylor Brenton, EVP, Operations & R&D | Sale under a trading plan | 2,829 | $5.42 | $15.3K | 264,978 | 6 Jul 2026 |
| 1 Jul 2026 | Badawi Paul, President and CEO | Sale under a trading plan | 28,684 | $5.42 | $155.5K | 6,122,472 | 6 Jul 2026 |
| 10 Jun 2026 | Encrantz Staffan, Director | Purchase | 14,100 | $4.88 | $68.8K | 1,434,283 | 11 Jun 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 2 Oct 2026 | Taylor Brenton, Officer | 2,988 | $26.5K | 2 Oct 2026 |
| 2 Oct 2026 | Rodberg James, Officer | 7,208 | $63.8K | 2 Oct 2026 |
| 2 Oct 2026 | Bauerlein Alison, Officer | 25,260 | $223.6K | 2 Oct 2026 |
| 1 Oct 2026 | HAYDEN JEREMY B., Former Officer | 2,746 | $24.8K | 1 Oct 2026 |
| 1 Oct 2026 | Badawi David, Officer, Director | 7,797 | $70.6K | 1 Oct 2026 |
| 1 Oct 2026 | Badawi Paul, Officer, Director | 29,653 | $268.3K | 1 Oct 2026 |
| 30 Sep 2026 | HAYDEN JEREMY B., Former Officer | 22,254 | $208.1K | 30 Sep 2026 |
| 4 Sep 2026 | HAYDEN JEREMY B., Former Officer | 12,219 | $101.3K | 4 Sep 2026 |
| 1 Sep 2026 | HAYDEN JEREMY B., Former Officer | 13,253 | $110.0K | 1 Sep 2026 |
| 17 Aug 2026 | HAYDEN JEREMY B., Former Officer | 12,014 | $97.8K | 17 Aug 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 8 Apr 2026 | KCK LTD. | 13G amended | 2.7% | 1.4M |
| 4 Feb 2026 | KCK LTD. | 13G amended | 7% | 3.7M |
| 21 Jan 2026 | BlackRock, Inc. | 13G | 5.01% | 2.7M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 1.2M | -12.37% | 3.52 |
| 30 Sep 2026 | 1.4M | +13.05% | 4.13 |
| 15 Sep 2026 | 1.3M | +2.39% | 8.5 |
| 31 Aug 2026 | 1.2M | +38.46% | 5.5 |
| 14 Aug 2026 | 883.6K | +6.89% | 2.12 |
| 31 Jul 2026 | 826.7K | -0.38% | 5.53 |
| 15 Jul 2026 | 829.8K | +14.21% | 5.03 |
| 30 Jun 2026 | 726.6K | -9.69% | 2.83 |
Funds that hold it
From each fund's latest Form 13F.
127 funds held it at 30 Jun 2026: 58 added and 30 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Long Focus Capital Management, LLC | 3,844,100 | $20.8M | +250,000 |
| BlackRock, Inc. | 3,083,108 | $16.7M | +251,176 |
| Americana Partners, LLC | 1,679,069 | $9.1M | +52 |
| Pathstone Holdings, LLC | 1,678,980 | $9.1M | -718,352 |
| Vanguard Capital Management LLC | 1,573,815 | $8.5M | +121,125 |
| Geode Capital Management, LLC | 958,565 | $5.2M | +43,121 |
| State Street Corp. | 835,452 | $4.5M | +424 |
| Acadian Asset Management LLC | 806,576 | $4.4M | +35,643 |
| B Group, Inc. | 970,000 | $3.7M | 0 |
| AQR Capital Management LLC | 397,558 | $2.2M | +259,041 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B